Medicines For Europe Calls For Security Of Supply Legislation
Increasing Inflation And Potential Price Cuts May Otherwise Impede Access
Medicines for Europe has urged the European Commission to enshrine security of supply considerations for essential medicines into legislature. Without these, additional cost containment measures for off-patent medicines under consideration by member states may ultimately threaten access by making production unsustainable for manufacturers.
You may also be interested in...
Medicines for Europe has urged the European Commission to exempt pharmaceutical suppliers, particularly those of biologic and antibiotic medicines, from any perspective energy rationing in the region, in line with new public guidelines.
Medicines for Europe has called for alterations to regulations concerning the off-patent drug sector, which it says will allow the industry to respond more effectively to the region’s dramatic rise in inflation.
Supply issues around breast cancer treatment tamoxifen in Germany demonstrate the damaging effects of European cost-containment measures, Medicines for Europe has warned, citing an “urgent need to revise unsustainable pricing and tendering policies.”